Literature DB >> 21590793

Sample size and power determination in joint modeling of longitudinal and survival data.

Liddy M Chen1, Joseph G Ibrahim, Haitao Chu.   

Abstract

Owing to the rapid development of biomarkers in clinical trials, joint modeling of longitudinal and survival data has gained its popularity in the recent years because it reduces bias and provides improvements of efficiency in the assessment of treatment effects and other prognostic factors. Although much effort has been put into inferential methods in joint modeling, such as estimation and hypothesis testing, design aspects have not been formally considered. Statistical design, such as sample size and power calculations, is a crucial first step in clinical trials. In this paper, we derive a closed-form sample size formula for estimating the effect of the longitudinal process in joint modeling, and extend Schoenfeld's sample size formula to the joint modeling setting for estimating the overall treatment effect. The sample size formula we develop is quite general, allowing for p-degree polynomial trajectories. The robustness of our model is demonstrated in simulation studies with linear and quadratic trajectories. We discuss the impact of the within-subject variability on power and data collection strategies, such as spacing and frequency of repeated measurements, in order to maximize the power. When the within-subject variability is large, different data collection strategies can influence the power of the study in a significant way. Optimal frequency of repeated measurements also depends on the nature of the trajectory with higher polynomial trajectories and larger measurement error requiring more frequent measurements.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21590793      PMCID: PMC3278672          DOI: 10.1002/sim.4263

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  16 in total

Review 1.  Simultaneous analysis of quality of life and survival data.

Authors:  L J Billingham; K R Abrams
Journal:  Stat Methods Med Res       Date:  2002-02       Impact factor: 3.021

2.  Surrogate markers and joint models for longitudinal and survival data.

Authors:  Jeremy M G Taylor; Yan Wang
Journal:  Control Clin Trials       Date:  2002-12

3.  A semiparametric likelihood approach to joint modeling of longitudinal and time-to-event data.

Authors:  Xiao Song; Marie Davidian; Anastasios A Tsiatis
Journal:  Biometrics       Date:  2002-12       Impact factor: 2.571

4.  Using trajectories from a bivariate growth curve as predictors in a Cox regression model.

Authors:  Qianyu Dang; Sati Mazumdar; Stewart J Anderson; Patricia R Houck; Charles F Reynolds
Journal:  Stat Med       Date:  2007-02-20       Impact factor: 2.373

5.  Joint modeling of survival and longitudinal data: likelihood approach revisited.

Authors:  Fushing Hsieh; Yi-Kuan Tseng; Jane-Ling Wang
Journal:  Biometrics       Date:  2006-12       Impact factor: 2.571

6.  Joint models for multivariate longitudinal and multivariate survival data.

Authors:  Yueh-Yun Chi; Joseph G Ibrahim
Journal:  Biometrics       Date:  2006-06       Impact factor: 2.571

7.  Model-based approaches to analysing incomplete longitudinal and failure time data.

Authors:  J W Hogan; N M Laird
Journal:  Stat Med       Date:  1997 Jan 15-Feb 15       Impact factor: 2.373

8.  A joint model for survival and longitudinal data measured with error.

Authors:  M S Wulfsohn; A A Tsiatis
Journal:  Biometrics       Date:  1997-03       Impact factor: 2.571

Review 9.  Basic concepts and methods for joint models of longitudinal and survival data.

Authors:  Joseph G Ibrahim; Haitao Chu; Liddy M Chen
Journal:  J Clin Oncol       Date:  2010-05-03       Impact factor: 44.544

10.  Random-effects models for longitudinal data.

Authors:  N M Laird; J H Ware
Journal:  Biometrics       Date:  1982-12       Impact factor: 2.571

View more
  20 in total

1.  Joint modeling of longitudinal outcomes and survival using latent growth modeling approach in a mesothelioma trial.

Authors:  Ping Wang; Wei Shen; Mark Ernest Boye
Journal:  Health Serv Outcomes Res Methodol       Date:  2012-06-05

2.  Assessing model fit in joint models of longitudinal and survival data with applications to cancer clinical trials.

Authors:  Danjie Zhang; Ming-Hui Chen; Joseph G Ibrahim; Mark E Boye; Ping Wang; Wei Shen
Journal:  Stat Med       Date:  2014-07-20       Impact factor: 2.373

3.  Joint modeling of longitudinal health-related quality of life data and survival.

Authors:  Divine E Ediebah; Francisca Galindo-Garre; Bernard M J Uitdehaag; Jolie Ringash; Jaap C Reijneveld; Linda Dirven; Efstathios Zikos; Corneel Coens; Martin J van den Bent; Andrew Bottomley; Martin J B Taphoorn
Journal:  Qual Life Res       Date:  2014-10-14       Impact factor: 4.147

4.  A random pattern mixture model for ordinal outcomes with informative dropouts.

Authors:  Chengcheng Liu; Sarah J Ratcliffe; Wensheng Guo
Journal:  Stat Med       Date:  2015-04-20       Impact factor: 2.373

Review 5.  Statistical Considerations for Analyses of Time-To-Event Endpoints in Oncology Clinical Trials: Illustrations with CAR-T Immunotherapy Studies.

Authors:  Yimei Li; Wei-Ting Hwang; Shannon L Maude; David T Teachey; Noelle V Frey; Regina M Myers; Allison Barz Leahy; Hongyan Liu; David L Porter; Stephan A Grupp; Pamela A Shaw
Journal:  Clin Cancer Res       Date:  2022-09-15       Impact factor: 13.801

6.  Power/sample size calculations for assessing correlates of risk in clinical efficacy trials.

Authors:  Peter B Gilbert; Holly E Janes; Yunda Huang
Journal:  Stat Med       Date:  2016-03-31       Impact factor: 2.373

7.  Flexible stopping boundaries when changing primary endpoints after unblinded interim analyses.

Authors:  Liddy M Chen; Joseph G Ibrahim; Haitao Chu
Journal:  J Biopharm Stat       Date:  2014       Impact factor: 1.051

Review 8.  Joint modeling of survival and longitudinal non-survival data: current methods and issues. Report of the DIA Bayesian joint modeling working group.

Authors:  A Lawrence Gould; Mark Ernest Boye; Michael J Crowther; Joseph G Ibrahim; George Quartey; Sandrine Micallef; Frederic Y Bois
Journal:  Stat Med       Date:  2014-03-14       Impact factor: 2.373

Review 9.  Application of Traditional and Emerging Methods for the Joint Analysis of Repeated Measurements With Time-to-Event Outcomes in Rheumatology.

Authors:  Liubov Arbeeva; Amanda E Nelson; Carolina Alvarez; Rebecca J Cleveland; Kelli D Allen; Yvonne M Golightly; Joanne M Jordan; Leigh F Callahan; Todd A Schwartz
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-04-08       Impact factor: 5.178

10.  The TNF-α -308 Promoter Gene Polymorphism and Chronic HBV Infection.

Authors:  Sirous Tayebi; Ashraf Mohamadkhani
Journal:  Hepat Res Treat       Date:  2012-10-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.